Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic Study of RLX030 in Acute Heart Failure
NCT01543854Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Jan 2013
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in Acute Heart Failure (AHF) comparing RLX030 with Placebo (2 arms). Primary endpoints: Peak change from baseline of Pulmonary Capillary Wedge Pressure (PCWP) at 20 hours and Peak change from baseline of Cardiac Index (CI) at 20 hours. Started Mar 2012; status: completed.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT01543854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01543854.